Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.

A blood donation service that partners with more than 300 hospitals in the southeast has suffered a ransomware attack that significantly reduced its capacity, according to a news release. 

OneBlood, a nonprofit blood center, said it is working with cybersecurity specialists, along with federal, state and local law enforcement, to respond to a “ransomware event” impacting its software system. 

“OneBlood takes the security of our network extremely seriously.  Our team reacted quickly to assess our systems and began an investigation to confirm the full nature and scope of the event,” said Susan Forbes, OneBlood senior vice president of corporate communications and public relations.

“Our comprehensive response efforts are ongoing and we are working diligently to restore full functionality to our systems as expeditiously as possible.” 

EVERYTHING YOU NEED TO KNOW ABOUT DONATING BLOOD DURING RED CROSS MONTH

The nonprofit said its centers remain operational and continue to collect, test and distribute blood to hospitals, but at a significantly reduced capacity.  

“We have implemented manual processes and procedures to remain operational. Manual processes take significantly longer to perform and impacts inventory availability,” said Forbes.

“In an effort to further manage the blood supply, we have asked the more than 250 hospitals we serve to activate their critical blood shortage protocols and to remain in that status for the time being.” 

YOUNG GIRL SURVIVES CANCER THANKS TO LITTLE SISTER’S LIFESAVING DONATION: ‘A PERFECT MATCH’

OneBlood’s Big Red Bus is ubiquitous at blood drives across the southeastern United States. (Peter Titmuss/Education Images/Universal Images Group via Getty Images)

The ransomware attack has created an urgent need for blood donations at OneBlood’s operational centers, the nonprofit shared in a call to action. The group said all blood types are needed, but specifically requested O positive, O negative and platelet donations.

Blood centers across the country are also donating blood and platelets to OneBlood, and the AABB Disaster Task Force is coordinating national resources to assist with additional blood products being sent to OneBlood, according to the news release.

BLOOD CANCER AWARENESS: COMMON TYPES, SIGNS AND TREATMENT OPTIONS

People wait to donate blood at the OneBlood center on June 13, 2016 in Orlando, Florida, following a mass shooting at a gay nightclub. (MANDEL NGAN/AFP via Getty Images)

“The blood supply cannot be taken for granted. The situation we are dealing with is ongoing. If you are eligible to donate, we urge you to please make an appointment to donate as soon as possible,” said Forbes.

OneBlood provides safe, available and affordable blood to 355 hospitals in Alabama, Florida, Georgia, North Carolina, South Carolina and Virginia, according to its website. 

The nonprofit operates more than 90 donor centers and its fleet of 250 Big Red Bus bloodmobiles are a familiar sight at blood drives throughout the southeastern United States. 

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Founded in 2012 when three independent Florida blood centers merged, OneBlood has grown to become the second-largest blood center in the United States. The nonprofit distributes more than 1 million blood products to hospitals annually. 

For more Health articles, visit www.foxnews.com/health.

• A new study found that smokers with type 2 diabetes taking Ozempic had fewer tobacco-related medical encounters compared to those using other diabetes medications.
• The study, based on electronic health records of nearly 229,000 patients, suggests a potential link between Ozempic and reduced tobacco use.
• Reports indicated that semaglutide, the active ingredient in Ozempic, might reduce smoking desire by affecting nicotine’s reward effects.

Smokers with type 2 diabetes taking Novo Nordisk’s Ozempic had fewer tobacco-related medical encounters and fewer interventions to help them quit smoking than those who received other diabetes drugs, according to a study of electronic health records published on Monday.

In the year after starting treatment, Ozempic users with a previous diagnosis of tobacco use disorder were up to 32% less likely to discuss tobacco use with a healthcare provider than those taking other diabetes medications. This was true even compared with those taking medicines in the same class, known as GLP-1 receptor agonists, researchers reported in Annals of Internal Medicine.

They were also up to 68% less likely to receive prescriptions for smoking cessation medication and up to 21% less likely to receive smoking cessation counseling.

DIABETES PATIENTS USING OZEMPIC, OTHER TREATMENTS INSTEAD OF INSULIN HAVE LOWER CANCER RISK, STUDY FINDS

The findings were drawn from electronic health record data on nearly 229,000 patients, including 6,000 recipients of Ozempic.

The researchers called for clinical trials to evaluate the potential of the drug’s active ingredient, semaglutide, for use in smoking cessation to backup the findings from this study sponsored by the U.S. National Institutes of Health.

They noted earlier reports have suggested a reduced desire to smoke in patients treated with semaglutide, possibly related to a dampening of addictive nicotine’s reward effects in the brain. Novo’s wildly popular weight-loss drug Wegovy has the same active ingredient.

The current study did not include data showing whether patients actually stopped or decreased tobacco use after starting on the various drugs.

While the observed reduction in tobacco disorder-related encounters might suggest reductions in tobacco use or relapses, it “could also reflect other scenarios, such as a reduced willingness to seek help to quit smoking,” the researchers acknowledged.

The classes of diabetes drugs looked at in the study included insulins, metformin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas, thiazolidinediones and other GLP-1’s than Ozempic.